Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne

被引:0
|
作者
Kast, K. [1 ,2 ]
Rhiem, K. [1 ]
Larsen, M. [1 ]
Wappenschmidt, B. [1 ]
Schmutzler, R. [1 ]
机构
[1] Univ Hosp Cologne, Med Fac, Ctr Hereditary Breast & Ovarian Canc, Ctr Integrated Oncol CIO, Cologne, Germany
[2] Univ Hosp Cologne, Ctr Hereditary Breast & Ovarian Canc, Ctr Integrated Oncol CIO, Kerpener Str 62, D-50937 Cologne, Germany
来源
CANCER MEDICINE | 2024年 / 13卷 / 03期
关键词
breast cancer; cancer prevention; genetic variants; next-generation sequencing; LI-FRAUMENI SYNDROME; MUTATION CARRIERS; RISK ASSESSMENT; FOLLOW-UP; RECOMMENDATIONS; CLASSIFICATION;
D O I
10.1002/cam4.6920
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Tumor protein p53 (TP53) pathogenic variant (PV) carriers are identified during genetic testing for hereditary causes of cancer. PVs in TP53 are associated with the Li-Fraumeni syndrome (LFS), and thus, surveillance and preventive measures are important for TP53 PV carriers. However, the penetrance of TP53 PVs can be low if the Chompret criteria are not fulfilled. In this study, we compared the phenotypic characteristics of families that did and did not fulfill the LFS criteria according to Chompret.Methods The German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) database was used to identify index patients with a likely pathogenic/pathogenic TP53 variant and their family members. The study investigated the type of variant, pedigree, age of onset, number of primary tumors, and histological type of BC.Results TP53 PV were present in the index cases of 35 families, 57% (20/35) of which fulfilled the Chompret criteria. The median age of onset at first BC diagnosis was lower in families that fulfilled the Chompret criteria compared to those who did not. Four of all diseased individuals were minors (4%; 4/105) when malignancy was first diagnosed. Sarcomas and brain tumors occurred in 10% (10/105) and in 7% (7/105) of all diseased persons, respectively. BC was the most frequently occurring first tumor (60%; 62/105) and additional malignancy (45%; 20/44) in this cohort. Subsequent malignancies developed in 31% (20/65) of the individuals who fulfilled the Chompret criteria compared with 15% (6/40) of those who did not.Conclusion The tumor spectrum and age of onset found in this study showed that tumors other than BC had low disease penetrance in TP53 PV carriers identified using the GC-HBOC criteria for genetic testing.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Intronic TP53 Germline Sequence Variants Modify the Risk in German Breast/Ovarian Cancer Families
    Xuan Liu
    Hans-Peter Sinn
    Hans Ulrich Ulmer
    Rodney J Scott
    Ute Hamann
    [J]. Hereditary Cancer in Clinical Practice, 2 (3)
  • [2] TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
    Grill, Sabine
    Ramser, Juliane
    Hellebrand, Heide
    Pfarr, Nicole
    Boxberg, Melanie
    Brambs, Christine
    Ditsch, Nina
    Meindl, Alfons
    Gross, Eva
    Meitinger, Thomas
    Kiechle, Marion
    Quante, Anne S.
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2021, 303 (06) : 1557 - 1567
  • [3] TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
    Sabine Grill
    Juliane Ramser
    Heide Hellebrand
    Nicole Pfarr
    Melanie Boxberg
    Christine Brambs
    Nina Ditsch
    Alfons Meindl
    Eva Groß
    Thomas Meitinger
    Marion Kiechle
    Anne S. Quante
    [J]. Archives of Gynecology and Obstetrics, 2021, 303 : 1557 - 1567
  • [4] Germline TP53 pathogenic variants and breast cancer: A narrative review
    Blondeaux, Eva
    Arecco, Luca
    Punie, Kevin
    Graffeo, Rossella
    Toss, Angela
    De Angelis, Carmine
    Trevisan, Lucia
    Buzzatti, Giulia
    Linn, Sabine C.
    Dubsky, Peter
    Cruellas, Mara
    Partridge, Ann H.
    Balman, Judith
    Paluch-Shimon, Shani
    Lambertini, Matteo
    [J]. CANCER TREATMENT REVIEWS, 2023, 114
  • [5] Phenotype and prognosis of patients with breast cancer and pathogenic TP53 variants
    Petry, Vanessa
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [6] Functional characterization of novel germline TP53 variants in Swedish families
    Kharaziha, Pedram
    Ceder, Sophia
    Axell, Olga
    Krall, Moritz
    Fotouhi, Omid
    Bohm, Stefanie
    Lain, Sonia
    Borg, Ake
    Larsson, Catharina
    Wiman, Klas G.
    Tham, Emma
    Bajalica-Lagercrantz, Svetlana
    [J]. CLINICAL GENETICS, 2019, 96 (03) : 216 - 225
  • [7] Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families
    Balz, V
    Prisack, HB
    Bier, H
    Bojar, H
    [J]. CANCER GENETICS AND CYTOGENETICS, 2002, 138 (02) : 120 - 127
  • [8] Cancer phenotype in 19 families with TP53 mutations
    Birch, JM
    Varley, JM
    Kelsey, AM
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 : 33 - 33
  • [9] Germline mutations of TP53 gene in breast cancer
    Damineni, Surekha
    Rao, Vadlamudi Raghavendra
    Kumar, Satish
    Ravuri, Rajasekar Reddy
    Kagitha, Sailaja
    Dunna, Nageswara Rao
    Digumarthi, Raghunadharao
    Satti, Vishnupriya
    [J]. TUMOR BIOLOGY, 2014, 35 (09) : 9219 - 9227
  • [10] TP53 Mutations in Breast and Ovarian Cancer
    Silwal-Pandit, Laxmi
    Langerod, Anita
    Borresen-Dale, Anne-Lise
    [J]. COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2017, 7 (01):